| Literature DB >> 26694323 |
Katherine C Teela1, Dane A De Silva2,3, Katie Chapman4, Anne R Synnes5, Diane Sawchuck6, Melanie Basso7, Robert M Liston8, Peter von Dadelszen9,10, Laura A Magee11,12,13,14.
Abstract
BACKGROUND: Administration of magnesium sulphate (MgSO4) to women with imminent preterm birth at <34 weeks is an evidence-based antenatal neuroprotective strategy to prevent cerebral palsy. Although a Society of Obstetricians and Gynaecologists of Canada (SOGC) national guideline with practice recommendations based on relevant clinical evidence exists, ongoing controversies about aspects of this treatment remain. Given this, we anticipated managed knowledge translation (KT) would be needed to facilitate uptake of the guidelines into practice. As part of the Canadian Institutes of Health Research (CIHR)-funded MAG-CP (MAGnesium sulphate to prevent Cerebral Palsy) project, we aimed to compare three KT methods designed to impact both individual health care providers and the organizational systems in which they work.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26694323 PMCID: PMC4688933 DOI: 10.1186/s12884-015-0785-8
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Characteristics of 1608 participants by type of KT method (N (%) or mean ± SD of column total unless otherwise specified)
| e-learning module ( | Site visits ( | Barriers & Facilitators Survey ( | |
|---|---|---|---|
| Health care provider type | |||
| Physicians | 458 (35.9 %) | 59 (40.4 %) | 92 (48.9 %) |
|
| - ‡ | 18 | 33 |
|
| 168 | 26 | 37 |
|
| 200 | 0 | 0 |
|
| 15 | 4 | 2 |
|
| 75 | 11 | 11 |
|
| 0 | 0 | 9 |
| Nurses | 439 (34.5 %) | 57 (39.0 %) | 87 (46.3 %) |
|
| 412 | 56 | 80 |
|
| 25 | 1 | 0 |
|
| 3 | 0 | 0 |
|
| 0 | 0 | 7 |
| Other | 177 (13.9 %) | 20 (13.7 %) | 7 (3.7 %) |
|
| 4 | 1 | 2 |
|
| 9 | 3 | 2 |
|
| 7 | 1 | 0 |
|
| 5 | 14 | 1 |
|
| 150 | 1 | 1 |
|
| 2 | 0 | 1 |
| Unclassified | 200 (15.7 %) | 10 (6.8 %) | 2 (1.1 %) |
| Province/Territory | |||
| British Columbia | 162 (12.7 %) | 10 (6.8 %) | 21 (11.2 %) |
| Alberta | 234 (18.4 %) | 80 (54.8 %) | 15 (8.0 %) |
| Saskatchewan | 45 (3.5 %) | 8 (5.5 %) | 16 (8.5 %) |
| Manitoba | 50 (3.9 %) | 0 | 0 |
| Ontario | 517 (40.6 %) | 25 (17.1 %) | 58 (30.9 %) |
| Quebec | 87 (6.8 %) | 5 (3.4 %) | 14 (7.4 %) |
| Newfoundland | 35 (2.7 %) | 6 (4.1 %) | 17 (9.0 %) |
| New Brunswick | 82 (6.4 %) | 12 (8.2 %)¶ | 34 (18.1 %) |
| Nova Scotia | 35 (2.7 %) | 13 (6.9 %) | |
| Prince Edward Island | 6 (0.5 %) | 0 | 0 |
| Yukon | 6 (0.5 %) | 0 | 0 |
| NWT | 9 (0.7) | 0 | 0 |
| Nunavut | 5 (0.4) | 0 | 0 |
| Unknown | 1 (0.0 %) | 0 | 0 |
| Works in a tertiary perinatal unit | 472 (37.0 %) | 146 (100 %) | 188 (100 %) |
| Small (<3000 del/yr) | 128/472 (27.1 %) | 13/146 (8.9 %) | 51/188 (27.1 %) |
| Medium (3000–4999 del/yr) | 52/472 (11.0 %) | 48/146 (32.9 %) | 29/188 (15.4 %) |
| Large (≥5000 del/yr) | 291/472 (61.7 %) | 85/146 (58.2 %) | 108/188 (57.5 %) |
| Missing | 1/472 (0.2 %) | 0 | 0 |
NWT (Northwest Territories), Del (deliveries), KT (knowledge translation), Obs/Gyn (Obstetrics and Gynaecology)
Note that the total % is broken down in various ways; each area until a bolded row adds to 100 %
* 13 sites were covered by 10 sites visits, as three small sites joined the visit at a larger centre
† Questionnaires were completed at 12/18 MAG-CP sites
‡ Not available as an option in the e-learning module
¶ Representatives from New Brunswick and Nova Scotia attended the site visit in Nova Scotia
Barriers to use of MgSO4 for fetal neuroprotection (N (%) responses for all responses that relate to barriers)
| Nodes | Sub-nodes | e-learning module ( | Site visits ( | Barriers & Facilitators Survey ( |
|---|---|---|---|---|
| Individual-level | 51 (42.9 %) | 47 (51.1 %) | 86 (58.5 %) | |
| Unsupportive attitudes and beliefs | 12 (10.1 %) | 3 (3.3 %) | 12 (8.2 %) | |
| Not within provider’s control | 4 (3.4 %) | 0 | 2 (1.4 %) | |
| No experience | 3 (2.5 %) | 1 (1.1 %) | 3 (2.0 %) | |
| Inadequate knowledge and understanding | Overall | 15 (12.6 %) | 18 (19.6 %) | 35 (23.8 %) |
|
| 0 | 3 | 18 | |
|
| 13 | 4 | 9 | |
|
| 2 | 11 | 8 | |
| Forgetting to administer MgSO4 | 1 (0.8 %) | 1 (1.1 %) | 3 (2.0 %) | |
| Fears | Overall | 14 (11.8 %) | 16 (17.4 %) | 13 (8.8 %) |
|
| 0 | 2 | 3 | |
|
| 0 | 2 | 0 | |
|
| 0 | 3 | 5 | |
|
| 14 | 9 | 5 | |
| Failure to implement guidelines | 0 | 1 (1.1 %)) | 4 (2.7 %) | |
| Evidence concerns (sufficiency and validity) | 2 (1.7 %) | 7 (7.6 %) | 14 (9.5 %) | |
| Institutional-level | 64 (53.8 %) | 34 (37.0 %) | 40 (27.2 %) | |
| Unsupportive institutional culture | 2 (1.7 %) | 3 (3.3 %) | 3 (2.0 %) | |
| Timing and transport | 20 (16.8 %) | 17 (18.5 %) | 6 (4.1 %) | |
| Resource constraints | 31 (25.2 %) | 12 (13.0 %) | 20 (13.6 %) | |
| Policy development and implementation | 11 (9.2 %) | 2 (12.0 %) | 11 (7.5 %) | |
| Social-level | 4 (3.4 %) | 11 (12.0 %) | 21 (14.3 %) | |
| Lack of provider-institutional consensus | 1 (0.8 %) | 4 (4.3 %) | 15 (10.2 %) | |
| Inadequate interprovider communication | 0 | 7 (7.6 %) | 5 (3.4 %) | |
| Educating patients | 3 (2.5 %) | 0 | 1 (0.7 %) | |
MgSO4 (magnesium sulphate)
Note that the total % is broken down in various ways; each area until a bolded row adds to the % listed in the bolded row
Facilitators of use of MgSO4 for fetal neuroprotection (N (%) responses for all responses that relate to facilitators)*
| Nodes | Sub-nodes | Site visits ( | Barriers & Facilitators Survey ( |
|---|---|---|---|
| Individual-level | 17 (13.3 %) | 38 (22.2 %) | |
| Supportive attitudes and beliefs | 4 (3.1 %) | 9 (5.3 %) | |
| Knowledge and understanding | 8 (6.3 %) | 15 (8.8 %) | |
| Early adopters/mobilizers | 1 (0.8 %) | 9 (5.3 %) | |
| Comfort/experience using MgSO4 | 4 (3.1 %) | 5 (2.9 %) | |
| Institutional-level | 80 (62.5 %) | 107 (62.6 %) | |
| Policies and protocols | Overall | 34 (26.6 %) | 26 (15.2 %) |
|
| 5 | 6 | |
|
| 8 | 2 | |
|
| 8 | 3 | |
|
| 13 | 15 | |
| Local champion/opinion leader | 8 (6.3 %) | 11 (6.4 %) | |
| Facility characteristics | Overall | 38 (29.7 %) | 70 (40.9 %) |
|
| 18 | 38 | |
|
| 3 | 10 | |
|
| 5 | 4 | |
|
| 12 | 18 | |
| Social-level | 31 (24.2 %) | 26 (15.2 %) | |
| Patient voice/awareness | 4 (3.1 %) | 2 (1.2 %) | |
| Knowledge translation | 17 (13.3 %) | 5 (2.9 %) | |
| Community support | 2 (1.6 %) | 0 | |
| Communication and collaboration | 8 (6.3 %) | 19 (11.1 %) | |
* When the e-learning module was designed, a specific exploration of facilitators was not planned and therefore, undertaken
Response about general policy/protocol and not specific to pre-printed orders, pre-printed bags, or audit/feedback
Note that the total % is broken down in various ways; each area until a bolded row adds to the % listed in the bolded row
Responses for ‘knowledge needed’ (N (%) responses) for all responses that relate to knowledge needed)
| Nodes | Sub-nodes | Sub-sub-node | e-learning module ( | Site visits ( | Barriers & Facilitators Survey ( |
|---|---|---|---|---|---|
| Mechanism of action | 11 (5.9 %) | 2 (2.4 %) | 17 (26.2 %) | ||
| Administration | Overall | 47 (25.0 %) | 61 (71.8 %) | 26 (40.0 %) | |
| Transfer | 0 | 2 | 0 | ||
| Threatened preterm labour vs. imminent preterm birth | 3 | 10 | 0 | ||
| Timing of administration | 6 | 9 | 7 | ||
| Standards of practice | 4 | 10 | 2 | ||
| Re-treatment | 0 | 7 | 3 | ||
| Pre-printed orders | 1 | 0 | 0 | ||
| Policies and protocols | 8 | 3 | 7 | ||
| Multiple pregnancies | 1 | 0 | 0 | ||
| Gestational age | 8 | 7 | 2 | ||
| Drug interactions | 5 | 0 | 0 | ||
| Contraindications | 1 | 2 | 0 | ||
| Unclassified | 10 | 11 | 5 | ||
| Side effects and risks | Overall | 26 (13.8 %) | 16 (18.8 %) | 6 (9.2 %) | |
| Rapid delivery | 1 | 0 | 0 | ||
| Overuse | 1 | 1 | 0 | ||
| Interventions as a result of MgSO4 | 3 | 0 | 0 | ||
| Increased monitoring needed | 5 | 0 | 0 | ||
| Adverse physiological effects – neonate |
| 3 | 1 | 0 | |
|
| 1 | 0 | 0 | ||
|
| 6 | 3 | 0 | ||
|
| 0 | 1 | 2 | ||
|
| 1 | 0 | 0 | ||
| Adverse physiological effects – general (unspecified maternal/neonate) | 0 | 7 | 0 | ||
| Unclassified | 4 | 2 | 4 | ||
| KT tools | Overall | 7 (3.7 %) | 0 | 3 (4.6 %) | |
| Audit and feedback | 1 | 0 | 0 | ||
| Unclassified | 6 | 0 | 3 | ||
| Research | Overall | 46 (24.5 %) | 5 (5.9 %) | 13 (20.0 %) | |
| Further research | 33 | 3 | 5 | ||
| Evidence to date | 6 | 1 | 7 | ||
| Unclassifiable | 7 | 1 | 1 | ||
| Other uses and topics (not MgSO4 for fetal neuroprotection) | 30 (16.0 %) | 1 (1.2 %) | 0 | ||
| None stated | 21 (11.2 %) | 0 | 0 | ||
MgSO4 (magnesium sulphate)
Note that the total is broken down in various ways; each area until a bolded row adds to the total n listed in the bolded row
Summary of key results / findings unique to each KT format
| e-learning module | Site visits | B&F survey | |
|---|---|---|---|
| Respondents accessed | • Reached the largest number of participants across the widest geographic area | • Reached fewer practitioners, but of a similar scope in terms of roles within health care | • Most limited in terms of ‘other’ non-physician and non-nurse respondents |
| Barriers | • Most restricted breadth of fears listed | • Greatest spread of barriers across individual, institutional, and social levels | • More social-level barriers compared with other formats |
| Facilitators | -* | • Institutional-level most cited, followed by | • Institutional-level most cited, followed by |
| Knowledge needed | • Greatest number of responses calling for further research | • Information on administration cited most often | • Least amount of information provided |
| Method | • One-way | • Two-way | • One-way |
| Approximate cost | • $10,000 | • $17,500 (total) or $1750 per visit† | • Negligible (assumption)† |
B&F (Barriers and Facilitators)
* Facilitators were not included in the e-learning module format which was developed first
† As academic health care centre employees, salaries were considered to cover educational activities such as for MAG-CP. Site visit costs were based on travel expenses